Showing results (171-180 of 208) with videos related to
Sort By:
Pageof 21
JAMA Network Open|April 6, 2026
Longitudinal Patterns of Symptoms in Patients Undergoing Chemotherapy: A Secondary Analysis of a Cluster Randomized Clinical TrialRoshan Paudel, Alexi A Wright, Christine Cronin, et al.American Journal of Surgery|December 19, 2002
Frequency of sentinel lymph node metastases in patients with favorable breast cancer histologic subtypesSandra L Wong, Celia Chao, Michael J Edwards, et al.Journal of the National Cancer Institute|March 6, 2024
Effects of a change in recall period on reporting severe symptoms: an analysis of a pragmatic multisite trialRoshan Paudel, Andrea C Enzinger, Hajime Uno, et al.Journal of Global Oncology|September 23, 2018
American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and ActionsGabriel N Hortobagyi, Doug Pyle, Eduardo L Cazap, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
NCCN Guidelines implementation in the multidisciplinary Merkel Cell Carcinoma Program at the University of MichiganJennifer L Schwartz, Sandra L Wong, Scott A McLean, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Features predicting sentinel lymph node positivity in Merkel cell carcinomaJennifer L Schwartz, Kent A Griffith, Lori Lowe, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 24, 2025
Patient and staff experiences with an EHR-Integrated Symptom Management Program (eSyM) in oncologyChristine M Cronin, Fiona Barrett, Samira Dias, et al.Implementation Science Communications|June 16, 2025
Psychometric evaluation of the NoMAD instrument in cancer care settings: assessing factorial validity, measurement invariance, and differential item functioningMaja Kuharic, James Lorenz Merle, David Cella, et al.European Journal of Cancer (Oxford, England : 1990)|June 13, 2015
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcomaElizabeth J Davis, Rashmi Chugh, Lili Zhao, et al.Annals of Surgical Oncology|June 15, 2020
Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and ChangeE Shelley Hwang, Charles M Balch, Glen C Balch, et al.Pageof 21